|
|
|
| Clinical research sites aren’t just execution engines. They’re the quiet architects of tomorrow’s medicines, building trust one patient at a time, solving problems no protocol can predict, and keeping trials alive when everything else wants to slow them down. Save Our Sites exists for one purpose: to build sites to last. If you’re ready to stop patching and start building something enduring… This is the conference for you. One industry. One community. Shared solutions. |
|
|
|
| Poland: An Underestimated Clinical Trials Powerhouse | Guest Column | By Tomasz Szelag, Ryvu Therapeutics | Poland is not "one of the good options" or "an interesting emerging market," says Tomasz Szelag, head of clinical operations, Ryvu Therapeutics. Rather, it should be one of the first places sponsors look to run their clinical trials. |
|
|
| Trials Without Borders: Episode 5 | Video | By Trials Without Borders | We explore Canada's clinical trial ecosystem with expert panelists Erin Cherban (Chief Clinical Research Officer, Centre Advancing Health Outcomes/CIHR Pan-Canadian Network), Melissa Bomben (CEO, True North Innovation Agency and fractional COO of Biorasi), and Sergey Nikitin (Founder and President, Prime Site Research Solutions Inc.). |
|
|
|
| Regulatory Opportunities For Decentralized Clinical Trials | Article | By Anna Yang, Genentech, a member of the Roche Group | Project SHASTA, a pioneering effort to measure the benefits of decentralized trial elements, reveals significant regulatory opportunities that could shape the future of clinical research. |
|
|
| Is Your Clinical Trial Portfolio CTIS Compliant? | Infographic | Palleos | The Clinical Trials Regulation and its centralized digital platform, the Clinical Trials Information System (CTIS), are now mandatory. Are you prepared to navigate your next clinical trial in the EU? |
|
|
|
|
|
|
| 2 Expectations And 2 Warnings For The Year Ahead | From The Editor | By Dan Schell, chief editor, Clinical Leader | Just when I thought I was done with 2026 predictions for the clinical trial industry, three members of my editorial board emailed me some great ones. What’s interesting is that two of these submissions, coincidentally, are focused on optimism for AI. In contrast, Denise Bronner’s forecast for the coming year is much more … well, dire. |
|
|
| Why Use Scorecards To Make Vendor Selection Decisions | Article | By Kalyan Obalampalli, ClinAI | Scorecards enable structured, unbiased vendor selection by transforming complex clinical trial decisions into transparent, data-driven evaluations — ensuring operational excellence and regulatory compliance. |
|
|
|
|
| Integrating Early Development With Clinical Supply | Webinar | Catalent | In the era of seamless development, reducing time to the clinic and getting rapid approval is key. An integrated approach can accelerate timelines, avoid communication pitfalls, and improve outcomes. |
|
|
| How To Capture Growth In The Expanding Metabolic Drug Market | Article | By Dr. Andrew Lewis, Dr. Andreas Reichl, and Matt Paterson, Quotient Sciences | Driven by GLP-1 success and rising obesity rates, R&D investment in metabolic disease therapies now rivals oncology, demanding rapid development to overcome market challenges. |
|
|
|
|
CHOOSE YOUR OWN ADVENTURE |
|
|
|
| You're receiving the Thursday edition of the Clinical Leader newsletter, focusing on Outsourcing Models and Regulatory & Compliance. To make changes to your newsletter selections, update your topic preferences. - Clinical Sites | Patient Centricity | Patient Recruitment (Monday)
- Clinical Trial Technology (Tuesday)
- Decentralized Trials | Trial Management (Wednesday)
- Outsourcing Models | Regulatory & Compliance (Thursday)
- Clinical Data Management & Analytics | Trial Monitoring (Friday)
Learn more about our personalized newsletters here. |
|
|
| Connect With Clinical Leader: |
|
|
|
